Literature DB >> 19943873

Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).

R Gopalakrishnan1, U Hedner, S Ghosh, R C Nayak, T C Allen, U R Pendurthi, L V M Rao.   

Abstract

BACKGROUND: Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors. Given the short biological half-life of rFVIIa, it is unclear how rFVIIa could be effective in prophylactic treatment.
OBJECTIVES: To examine the extravascular distribution of pharmacologically administered rFVIIa to obtain clues on how rFVIIa could work in prophylaxis.
METHODS: Recombinant mouse FVIIa tagged with AF488 fluorophore (AF488-FVIIa) was administered into mice via the tail vein. At different time intervals following the administration, mice were exsanguinated and various tissues were collected. The tissue sections were processed for immunohistochemistry to evaluate distribution of rFVIIa.
RESULTS: rFVIIa, immediately following the administration, associated with the endothelium lining of large blood vessels. Within 1 h, rFVIIa bound to endothelial cells was transferred to the perivascular tissue surrounding the blood vessels and thereafter diffused throughout the tissue. In the liver, rFVIIa was localized to sinusoidal capillaries and accumulated in hepatocytes. In bone, rFVIIa was accumulated in the zone of calcified cartilage and some of it was retained there for a week. The common finding of the present study is that rFVIIa in extravascular spaces was mostly localized to regions that contain TF expressing cells.
CONCLUSIONS: The present study demonstrates that pharmacologically administered rFVIIa readily associates with the vascular endothelium and subsequently enters into extravascular spaces where it is likely to bind to TF and is retained for extended time periods. This may explain the prolonged pharmacological effect of rFVIIa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19943873      PMCID: PMC2849270          DOI: 10.1111/j.1538-7836.2009.03696.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  29 in total

1.  Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint.

Authors:  B R Saxon; D Shanks; C B Jory; V Williams
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

2.  Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.

Authors:  E Erhardtsen; P Nilsson; M Johannessen; M S Thomsen
Journal:  J Clin Pharmacol       Date:  2001-08       Impact factor: 3.126

Review 3.  Pharmacokinetics of recombinant activated factor VII (rFVIIa).

Authors:  E Erhardtsen
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

4.  Haemostatic factors in human peripheral afferent lymph.

Authors:  G J Miller; D J Howarth; J C Attfield; C J Cooke; M N Nanjee; W L Olszewski; J H Morrissey; N E Miller
Journal:  Thromb Haemost       Date:  2000-03       Impact factor: 5.249

5.  Properties of factor VIIa/tissue factor complexes in an umbilical vein model.

Authors:  F E Almus; L V Rao; R A Fleck; S I Rapaport
Journal:  Blood       Date:  1990-07-15       Impact factor: 22.113

6.  Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor.

Authors:  A Iakhiaev; U R Pendurthi; J Voigt; M Ezban; L Vijaya Mohan Rao
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

7.  Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.

Authors:  W Y Tcheng; J Donkin; S Konzal; W-Y Wong
Journal:  Haemophilia       Date:  2004-05       Impact factor: 4.287

8.  Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.

Authors:  Natascha C J Mathijssen; Rosalinde Masereeuw; Kitty Verbeek; J Maurice Lavergne; Jean-Marc Costa; Waander L van Heerde; Irena R O Nováková
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

9.  Endothelial cell protein C receptor cellular localization and trafficking: potential functional implications.

Authors:  Ramesh C Nayak; Prosenjit Sen; Samit Ghosh; Ramakrishnan Gopalakrishnan; Charles T Esmon; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

10.  Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model.

Authors:  F E Almus; L V Rao; S I Rapaport
Journal:  Arterioscler Thromb       Date:  1993-01
View more
  23 in total

1.  Factor VIIa binding to endothelial cell protein C receptor: differences between mouse and human systems.

Authors:  Prosenjit Sen; Curtis A Clark; Ramakrishnan Gopalakrishnan; Ulla Hedner; Charles T Esmon; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Thromb Haemost       Date:  2012-02-28       Impact factor: 5.249

2.  Endothelial protein C receptor is required for tissue factor ternary complex signaling in the mouse.

Authors:  J Disse; W Ruf
Journal:  J Thromb Haemost       Date:  2011-12       Impact factor: 5.824

Review 3.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

4.  Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; SubbaRao V Madhunapantula; Jerry Grandoni; L Vijaya Mohan Rao
Journal:  Thromb Haemost       Date:  2019-05-26       Impact factor: 5.249

5.  Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.

Authors:  T Knudsen; A T Kristensen; T C Nichols; H Agersø; A L Jensen; M Kjalke; M Ezban; M Tranholm
Journal:  Haemophilia       Date:  2011-06-06       Impact factor: 4.287

6.  Redistribution and hemostatic action of recombinant activated factor VII associated with platelets.

Authors:  Irene Lopez-Vilchez; Ulla Hedner; Carmen Altisent; Maribel Diaz-Ricart; Gines Escolar; Ana M Galan
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

7.  Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male.

Authors:  Thomas J Cramer; Kristin Anderson; Karanjia Navaz; Justin M Brown; Laurent O Mosnier; Annette von Drygalski
Journal:  Blood Cells Mol Dis       Date:  2015-11-10       Impact factor: 3.039

8.  Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients.

Authors:  H Agersø; D F Brophy; H Pelzer; E J Martin; M Carr; U Hedner; M Ezban
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

9.  Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection.

Authors:  Prosenjit Sen; Ramakrishnan Gopalakrishnan; Hema Kothari; Shiva Keshava; Curtis A Clark; Charles T Esmon; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2011-01-20       Impact factor: 22.113

Review 10.  Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.

Authors:  John Puetz
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.